乳腺生物反应器_膜生物反应器原理_一次性生物反应器(5)

Anima mammary gland reactor used for chicken fabricii bursa virus vaccine

Animal mammary gland reactor is a key bioengineering project of the national "863" plan, with world-leading technologies in the bioengineering field. The aim of the project is to utilize animal mammary gland to produce rare proteins and other bio-tech porducts used in medicine and agriculture, so as to substitute products extracted directly from human organs, produced by E.Coli bacteria or by isolated single animal cells. This new technology has the advantages of low production cost,high product purity,and good economical effects, thus has extremely high commercial values. Because of shortage of human blood and fear of blood contamination, using transgenic animal mammary gland for production is very important especially in the area of producing proteins for medical use. These products are mainly used to treat coma, edema, and low protein symptoms caused by loss of blood, open wound, cancer and other diseases, and they are urgently needed (Annual sales of 2 million USD of medical protein in the world). There is a huge market potential of developing transgenic animal mammary gland reactor technology. The project is undertaken by a joint effort of China Agriculture University and Shenzhen Lupeng Company. For the project, we have established "Transgenic Animal Engineering Center" at the national level in Beijing, and established "Transgenic Animal Breeding Base" in both Beijing and Shenzhen. The researchers have successfully transplanted embryos to receptor sheep and receptor cattle, and the gene output from the transgenic cattle, sheep and rabbit has been over unit of gram. Now industrialized project is transgenic sheep that has fruitfully expressed Fabricii bursa virus vaccine. The total investment for this project is 70 million RMB(8.43 million USD),with a building-up period of 5 years, which includes building the "Transgenic Animal Engineering Center", building a breeding base for 600 transgenic cattle, and building a bioengineering pharmaccutical plant. The goal of the project is to achieve an annual production capacity of 120 kilograms of vaccine, with annual production value of 75 million yuan, annual sales of 60 million RMB(7.23 million USD),annual profit of 48 million RMB(5.78 million USD),and annual tax payment of 12.96 million RMB(1.56 million USD).一篇《转基因小鼠动物模型的制备》望共享。